Prognostic DNA Methylation Markers for Renal Cell Carcinoma: A Systematic Review

References

• Ferlay J , SoerjomataramI , DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 . Int. J. Cancer136 ( 5 ), E359 – E386 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A , CarrascoJC , ChengLet al. 2009 update on the classification of renal epithelial tumors in adults . Int. J. Urol.16 ( 5 ), 432 – 443 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Rydzanicz M , WrzesinskiT , BluyssenHA , WesolyJ . Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications . Cancer Lett.341 ( 2 ), 111 – 126 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• American Cancer Society . Cancer Facts & Fetals 2015 ( 2015 ). www.cancer.org/research/cancerfactsstatistics/cancerfactsfetals2015/index
   Google Scholar
• Kattan MW , ReuterV , MotzerRJ , KatzJ , RussoP . A postoperative prognostic nomogram for renal cell carcinoma . J. Urol.166 ( 1 ), 63 – 67 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Frank I , BluteML , ChevilleJCet al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score . J. Urol.168 ( 6 ), 2395 – 2400 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Zisman A , PantuckAJ , DoreyFet al. Improved prognostication of renal cell carcinoma using an integrated staging system . J. Clin. Oncol.19 ( 6 ), 1649 – 1657 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Zisman A , PantuckAJ , WiederJet al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma . J. Clin. Oncol.20 ( 23 ), 4559 – 4566 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Patard JJ , KimHL , LamJSet al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study . J. Clin. Oncol.22 ( 16 ), 3316 – 3322 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Zigeuner R , HuttererG , ChromeckiTet al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology . Eur. Urol.57 ( 1 ), 102 – 109 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wei JH , HaddadA , WuKJet al. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma . Nat. Commun.6 , 8699 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Brooks SA , BrannonAR , ParkerJSet al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma . Eur. Urol.66 ( 1 ), 77 – 84 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Baylin SB . DNA methylation and gene silencing in cancer . Nat. Clin. Pract. Oncol.2 ( Suppl. 1 ), S4 – S11 ( 2005 ).
   PubMedGoogle Scholar
• Morris MR , MaherER . Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics . Genome Med.2 ( 9 ), 59 ( 2010 ).
   PubMedGoogle Scholar
• Morris MR , LatifF . The epigenetic landscape of renal cancer . Nat. Rev. Nephrol.13 ( 1 ), 47 – 60 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Laird PW . The power and the promise of DNA methylation markers . Nat. Rev. Cancer3 ( 4 ), 253 – 266 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Haas NB , ManolaJ , UzzoRGet al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, Phase III trial . Lancet387 ( 10032 ), 2008 – 2016 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ravaud A , MotzerRJ , PandhaHSet al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy . N. Engl. J. Med.375 ( 23 ), 2246 – 2254 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Patel DN , FiglinRA , KimHL . Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?Clin. Adv. Hematol. Oncol.14 ( 11 ), 907 – 914 ( 2016 ).
   PubMedGoogle Scholar
• Moher D , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement . PLoS Med.6 ( 7 ), e1000097 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Liberati A , AltmanDG , TetzlaffJet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration . PLoS Med.6 ( 7 ), e1000100 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• McShane LM , AltmanDG , SauerbreiWet al. Reporting recommendations for tumor marker prognostic studies (REMARK) . J. Natl Cancer Inst.97 ( 16 ), 1180 – 1184 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Altman DG , McShaneLM , SauerbreiW , TaubeSE . Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration . BMC Med.10 , 51 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hayes DF , BastRC , DeschCEet al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers . J. Natl Cancer Inst.88 ( 20 ), 1456 – 1466 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Simon RM , PaikS , HayesDF . Use of archived specimens in evaluation of prognostic and predictive biomarkers . J. Natl. Cancer Inst.101 ( 21 ), 1446 – 1452 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• de Martino M , KlatteT , HaitelA , MarbergerM . Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker . Cancer118 ( 1 ), 82 – 90 ( 2012 ).
   PubMedGoogle Scholar
• Morris MR , RickettsC , GentleDet al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma . Oncogene29 ( 14 ), 2104 – 2117 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Atschekzei F , HennenlotterJ , JanischSet al. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence . Epigenetics7 ( 5 ), 447 – 457 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ricketts CJ , HillVK , LinehanWM . Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA kidney renal clear cell carcinoma (KIRC) project . PLoS ONE , 9 ( 1 ), e85621 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• van Vlodrop IJ , BaldewijnsMM , SmitsKMet al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma . Am. J. Pathol.176 ( 2 ), 575 – 584 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• van Vlodrop IJH , JoostenSC , De MeyerTet al. A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients . Clin. Cancer Res.23 ( 8 ), 2006 – 2018 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Morris MR , RickettsCJ , GentleDet al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma . Oncogene30 ( 12 ), 1390 – 1401 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Peters I , EggersH , AtschekzeiFet al. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression . BJU Int.110 ( 2, Pt 2 ), E144 – E152 ( 2012 ).
   PubMedGoogle Scholar
• Peters I , GebauerK , DubrowinskajaNet al. GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma . Oncol. Rep.31 ( 4 ), 1523 – 1530 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ellinger J , HollD , NuhnPet al. DNA hypermethylation in papillary renal cell carcinoma . BJU Int.107 ( 4 ), 664 – 669 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kawai Y , SakanoS , SuehiroYet al. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma . Ann. Oncol.21 ( 8 ), 1612 – 1617 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Klacz J , WierzbickiPM , WronskaAet al. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma . Int. J. Oncol.48 ( 1 ), 55 – 66 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lin YL , WangYL , FuXL , MaJG . Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma . Med. Sci. Monit.20 , 2380 – 2385 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Peters I , DubrowinskajaN , AbbasMet al. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies . PLoS ONE9 ( 3 ), e91440 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dubrowinskaja N , GebauerK , PetersIet al. Neurofilament heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response . Cancer Med.3 ( 2 ), 300 – 309 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Yamada D , KikuchiS , WilliamsYNet al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma . Int. J. Cancer118 ( 4 ), 916 – 923 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ricketts CJ , MorrisMR , GentleDet al. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma . Clin. Epigenetics5 ( 1 ), 16 ( 2013 ).
   PubMedGoogle Scholar
• Li H , WangJ , XiaoWet al. Epigenetic alterations of Kruppel-like factor 4 and its tumor suppressor function in renal cell carcinoma . Carcinogenesis34 ( 10 ), 2262 – 2270 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kagara I , EnokidaH , KawakamiKet al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma . J. Urol.180 ( 1 ), 343 – 351 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hildebrandt MA , GuJ , LinJet al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma . Oncogene29 ( 42 ), 5724 – 5728 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Girgis AH , IakovlevVV , BeheshtiBet al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma . Cancer Res.72 ( 20 ), 5273 – 5284 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gebauer K , PetersI , DubrowinskajaNet al. Hsa-mir-124–3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma . Br. J. Cancer108 ( 1 ), 131 – 138 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fisel P , KruckS , WinterSet al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome . Clin. Cancer Res.19 ( 18 ), 5170 – 5181 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fisel P , StuhlerV , BedkeJet al. MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma . Oncotarget6 ( 31 ), 30615 – 30627 ( 2015 ).
   PubMedGoogle Scholar
• Eggers H , SteffensS , GrosshennigAet al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma . Int. J. Oncol.40 ( 5 ), 1650 – 1658 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Deckers IA , SchoutenLJ , Van NesteLet al. Promoter methylation of CDO1 identifies clear-cell renal cell cancer patients with poor survival outcome . Clin. Cancer Res.21 ( 15 ), 3492 – 3500 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Christoph F , WeikertS , KempkensteffenCet al. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications . Clin. Cancer Res.12 ( 17 ), 5040 – 5046 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Breault JE , ShiinaH , IgawaMet al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma . Clin. Cancer Res.11 ( 2, Pt 1 ), 557 – 564 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Awakura Y , NakamuraE , ItoN , KamotoT , OgawaO . Methylation-associated silencing of TU3A in human cancers . Int. J. Oncol.33 ( 4 ), 893 – 899 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network . Comprehensive molecular characterization of clear cell renal cell carcinoma . Nature499 ( 7456 ), 43 – 49 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Golovastova MO , TsoyLV , BocharnikovaAVet al. The cancer-retina antigen recoverin as a potential biomarker for renal tumors . Tumour Biol.37 ( 7 ), 9899 – 9907 ( 2016 ).
   PubMedGoogle Scholar
• Lin YL , GuiSL , GuoH , MaJG , LiWP . Protocadherin17 promoter methylation is a potential predictive biomarker in clear cell renal cell carcinoma . Med. Sci. Monit.21 , 2870 – 2876 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mitsui Y , HirataH , ArichiNet al. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways . Oncotarget6 ( 11 ), 9577 – 9591 ( 2015 ).
   PubMedGoogle Scholar
• Zhao H , LeppertJT , PeehlDM . A protective role for androgen receptor in clear cell renal cell carcinoma based on mining TCGA data . PLoS ONE11 ( 1 ), e0146505 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Chen G , WangY , WangL , XuW . Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma . Oncotarget8 ( 3 ), 5268 – 5280 ( 2017 ).
   PubMedGoogle Scholar
• Fabrizio FP , CostantiniM , CopettiMet al. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma . Oncotarget8 ( 7 ), 11187 – 11198 ( 2017 ).
   PubMedGoogle Scholar
• Pompas-Veganzones N , SandonisV , Perez-LanzacAet al. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer . Tumour Biol.37 ( 10 ), 14301 – 14310 ( 2016 ).
   PubMedGoogle Scholar
• Wang ZR , WeiJH , ZhouJCet al. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma . Oncotarget7 ( 21 ), 31508 – 31519 ( 2016 ).
   PubMedGoogle Scholar
• Arai E , KanaiY , UshijimaSet al. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues . Int. J. Cancer119 ( 2 ), 288 – 296 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Tian Y , AraiE , GotohMet al. Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes . BMC Cancer14 , 772 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Urakami S , ShiinaH , EnokidaHet al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA . Clin. Cancer Res.12 ( 23 ), 6989 – 6997 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Xu B , ZhangL , LuoCet al. Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma . Int. J. Mol. Sci.16 ( 1 ), 1051 – 1065 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yoo KH , ParkYK , ChangSG . DNA hypomethylation of interleukin 8 in clear cell renal cell carcinoma . Oncol. Lett.5 ( 1 ), 39 – 42 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yoo KH , ParkYK , KimHS , JungWW , ChangSG . Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma . Pathol. Int.60 ( 10 ), 661 – 666 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Yoo KH , ParkYK , KimHS , JungWW , ChangSG . Identification of MAPK10 as a novel epigenetic marker for chromophobe kidney cancer . Pathol. Int.61 ( 1 ), 52 – 54 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Smits KM , SchoutenLJ , van DijkBAet al. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis . Clin. Cancer Res.14 ( 3 ), 782 – 787 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Young AC , CravenRA , CohenDet al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma . Clin. Cancer Res.15 ( 24 ), 7582 – 7592 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Vidaurreta M , MaestroML , Sanz-CaslaMTet al. Inactivation of p16 by CpG hypermethylation in renal cell carcinoma . Urol. Oncol.26 ( 3 ), 239 – 245 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• van Vlodrop IJ , NiessenHE , DerksSet al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17 ( 13 ), 4225 – 4231 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kramar A , NegrierS , SylvesterRet al. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project . Ann. Oncol.26 ( 12 ), 2392 – 2398 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gumz ML , ZouH , KreinestPAet al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma . Clin. Cancer Res.13 ( 16 ), 4740 – 4749 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dreijerink K , BragaE , KuzminIet al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis . Proc. Natl Acad. Sci. USA98 ( 13 ), 7504 – 7509 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• McShane LM , AltmanDG , SauerbreiW . Identification of clinically useful cancer prognostic factors: what are we missing?J. Natl Cancer Inst.97 ( 14 ), 1023 – 1025 ( 2005 ).
   PubMedGoogle Scholar